Table 4. Selected patients with matched sex, age and FI score from the major and the minor group respectively for EV bleeding analysis.
| Parameter | No NSBB (matched, n=183) | NSBB (matched, n=183) | P value |
|---|---|---|---|
| Male (n, %) | 148 (80.87) | 148 (80.87) | 1.00 |
| Age (years, mean ± SD) | 54.68±11.71 | 54.68±11.71 | 1.00 |
| Etiology, n (%) | <0.01 | ||
| HBV | 80 (43.71) | 76 (41.53) | |
| HCV | 51 (27.87) | 29 (15.85) | |
| Alcohol | 26 (14.21) | 48 (26.23) | |
| Others | 26 (14.21) | 30 (16.39) | |
| Follow-up duration (months, mean ± SD) | |||
| To EV bleeding | 10.46±3.78 | 3.97±3.57 | <0.01 |
| Outcome | |||
| Esophageal variceal bleeding in 1 year (n, %) | 22 (12.02) | 160 (87.43) | <0.01 |
| Baseline laboratory value (mean ± SD) | |||
| AST (U/L) | 89.14±88.74 | 95.19±94.44 | 0.53 |
| ALT (U/L) | 58.24±60.64 | 51.29±49.73 | 0.23 |
| Cr (mg/dL) | 1.39±1.64 | 1.48±1.75 | 0.62 |
| Na (mEq/L) | 136.50±9.61 | 136.80±5.73 | 0.72 |
| K (mEq/L) | 3.93±0.56 | 4.09±1.44 | 0.18 |
| Bilirubin-total (mg/dL) | 3.46±5.55 | 2.85±3.34 | 0.20 |
| Albumin (g/dL) | 3.21±0.71 | 3.10±0.64 | 0.12 |
| PT-INR | 1.36±0.34 | 1.35±0.28 | 0.89 |
| Hb (g/dL) | 10.91±2.54 | 10.08±2.57 | <0.01 |
| WBC (×1,000/μL) | 6.31±3.77 | 7.23±4.37 | 0.03 |
| Platelet (×1,000/μL) | 107.20±57.99 | 118.00±70.84 | 0.11 |
| r-GT | 172.50±269.30 | 279.30±380.30 | 0.01 |
| Cholesterol | 151.40±48.76 | 161.00±49.88 | 0.17 |
| Prognostic systems (mean ± SD) | |||
| CTP score | 6.80±1.67 | 6.89±1.37 | 0.61 |
| MELD score | 14.65±6.63 | 14.43±5.19 | 0.74 |
| MELD-Na score | 16.49±8.80 | 15.54±6.41 | 0.27 |
| PALBI score | −2.54±0.73 | −2.51±0.69 | 0.74 |
| PALBI grade 1 (n, %) | 100 (54.64) | 92 (50.27) | 0.41 |
| PALBI grade 2 (n, %) | 39 (21.31) | 50 (27.32) | |
| PALBI grade 3 (n, %) | 44 (24.04) | 41 (22.40) | |
| Spleen diameter | 5.97±1.15 | 6.11±1.19 | 0.39 |
| GUCI | 4.90±7.98 | 4.54±5.94 | 0.64 |
| Gamma-glutamyl transpeptidase-to-platelet ratio (GPR) | 2.68±3.62 | 3.88±5.26 | 0.04 |
| Gamma-glutamyl transpeptidase-to-albumin ratio (GAR) | 5.41±8.17 | 9.00±11.47 | <0.01 |
| AST/ALT ratio | 1.87±1.43 | 2.36±2.23 | 0.01 |
| AST to platelet ratio index (APRI) | 3.27±3.81 | 3.26±4.03 | 0.98 |
| Platelet count to spleen diameter (PC/SD) | 18.78±10.70 | 20.29±13.39 | 0.37 |
| Fibrosis-4-index (FIB-4) | 7.75±6.52 | 8.53±8.91 | 0.34 |
| Fibrosis index (FI) | 3.72±0.95 | 3.72±0.95 | 0.99 |
| King’s score | 89.47±172.65 | 80.07±99.28 | 0.54 |
| Log score | 3.09±2.86 | 3.53±3.48 | 0.20 |
| Lok index | 0.84±0.18 | 0.88±0.17 | 0.07 |
| Portal vein size | 1.14±0.25 | 1.15±0.26 | 0.93 |
| Forns index | 10.77±1.82 | 10.81±1.72 | 0.88 |
NSBB, non-selective beta-blockers; EV, esophageal variceal; AST, aspartate aminotransferase; ALT, alanine aminotransferase.